Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Disc Medicine, IncUpdated: Aug 19, 2026Locations: 8
Eligibility criteria

Aged 18 years or older at the time of signing the informed consent form (ICF). [+17]

Participants who are receiving regularly scheduled blood (RBC) transfusion thera... [+17]

Read more
Status: Recruiting

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

Participants needed: 150
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Disc Medicine, IncUpdated: Aug 12, 2026Locations: 30
Eligibility criteria

Age 18 years or older at the time of signing the informed consent form (ICF). [+60]

Hereditary hemochromatosis [+55]

Read more
Status: Available

Expanded Access Program of Bitopertin For Participants With EPP or XLP

The goal of this expanded access program is to provide bitopertin to patients with EPP and XLP who have no satisfactory treatment options available in the US and to learn if bitopertin is safe to treat EPP and XLP.

Trial details
Age: 12+Biological sex: AllType: Expanded AccessSponsor: Disc Medicine, IncUpdated: Aug 3, 2026Locations: 5
Eligibility criteria

Written informed consent (and assent where applicable). [+4]

Known hypersensitivity to bitopertin or its excipients. [+13]

Read more
Status: Recruiting

Study of DISC-0974-201 in Participants With IBD and Anemia

This is a Phase 2, multicenter, randomized, double-blind placebo-controlled study of DISC-0974 to evaluate safety, tolerability, and efficacy in participants with IBD and anemia of inflammation.

Participants needed: 21
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Disc Medicine, IncUpdated: Aug 3, 2026Locations: 14
Eligibility criteria

Aged ≥18 years at the time of signing informed consent. [+18]

Treatment within 2 days prior to screening with oral iron or iron-containing sup... [+32]

Read more